Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization
|ClinicalTrials.gov Identifier: NCT00681603|
Recruitment Status : Completed
First Posted : May 21, 2008
Last Update Posted : May 21, 2008
- Purpose:Our animal study demonstrated the effectiveness of subconjunctival injection of bevacizumab in the inhibition of corneal neovasculization formation. The purpose of this human interventional study is to report the treatment outcome of subconjunctival injection of bevacizumab in patients with corneal neovascularization.
- Material and methods: We enrolled 13 patients with unilateral or bilateral clinically significant corneal neovascularization during Aug. 2007 to Jan. 2008. Subconjunctival injection of bevacizumab once per month for at most 7 times was performed according to clinical response.
- Main outcome measurements: resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity.
|Condition or disease||Intervention/treatment|
|Lipid Keratopathy Penetrating Keratoplasty Herpetic Keratopathy Rosacea||Drug: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization|
|Study Start Date :||August 2007|
|Primary Completion Date :||February 2008|
|Study Completion Date :||February 2008|
13 cases that accepted subconjunctival injection of bevacizumab
Drug: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)
subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
Other Name: bevacizumab ( Avastin )
- Resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity [ Time Frame: prospective ]
- major side effects [ Time Frame: prospective ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00681603
|Department of Ophthalmology, National Taiwan University Hospital,|
|Taipei, Taiwan, 100|
|Principal Investigator:||Wei-Li Chen||National Taiwan University Hospital|